Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

Results of a phase I/II British Society

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation

✍ Z.Y. Lim; G. Cook; P.R. Johnson; Anne Parker; M. Zuckerman; D. Marks; H. Wiltshi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 218 KB

This multi-centre randomized study assessed the bioavailability of ganciclovir in patients undergoing alemtuzumab-based reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) after oral administration of valganciclovir. Patients were randomized to 2 groups receiving eit